Clinical Trials
Recently Published Documents


TOTAL DOCUMENTS

74500
(FIVE YEARS 35470)

H-INDEX

320
(FIVE YEARS 104)

2022 ◽  
Author(s):  
Jiachen Shi ◽  
Yanan Wang ◽  
Fan Jiang ◽  
Yuanfa Liu ◽  
Yong-Jiang Xu

Krill oil as a dietary supplement is popular for consumers. Several experimental and clinical trials have suggested that krill oil is beneficial for longevity and locomotion, but the underlying mechanisms...


AIDS ◽  
2021 ◽  
Vol 35 (Supplement 2) ◽  
pp. S183-S188
Author(s):  
W.D. Francois Venter ◽  
Simiso Sokhela ◽  
Alexandra Calmy ◽  
Luckyboy Mkhondwane ◽  
Bronwyn Bosch ◽  
...  
Keyword(s):  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Thomas B. Cwalina ◽  
Tarun K. Jella ◽  
Grigory A. Manyak ◽  
Andy Kuo ◽  
Atul F. Kamath

2021 ◽  
Author(s):  
Jacob Aday ◽  
Boris D. Heifets ◽  
Steven D. Pratscher ◽  
Ellen Bradley ◽  
Raymond Rosen ◽  
...  

Rationale: Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research.Objective: In this article, we review the many methodological challenges of conducting psychedelic clinical trials and provide recommendations for improving the rigor of future research.Results: We found that although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias. The subjective effects of a high-dose psychedelic are often so pronounced that it is difficult to mask participants to their treatment condition; the significant hype from positive media coverage on the clinical potential of psychedelics influences participants’ expectations for treatment benefit; and participant unmasking and treatment expectations can interact in such a way that makes psychedelic therapy highly susceptible to large placebo and nocebo effects. Specific recommendations to increase the success of masking procedures and reduce the influence of participant expectancies concern study development, participant recruitment and selection, incomplete disclosure of the study design, choice of active placebo condition, as well as the measurement of participant expectations and masking efficacy.Conclusion: Incorporating these design elements is intended to reduce the risk of bias in psychedelic clinical trials and thereby increase the ability to discern treatment-specific effects of psychedelic therapy


Author(s):  
Anders Granholm ◽  
Waleed Alhazzani ◽  
Lennie P. G. Derde ◽  
Derek C. Angus ◽  
Fernando G. Zampieri ◽  
...  

Author(s):  
Yuan-Li Shen ◽  
Xin Wang ◽  
Sirisha Mushti ◽  
Flora Mulkey ◽  
Jiaxi Zhou ◽  
...  

2021 ◽  
pp. 106646
Author(s):  
Josephine Harrington ◽  
Pishoy Gouda ◽  
Justin Ezekowitz ◽  
Robert J. Mentz
Keyword(s):  

2021 ◽  
Vol 9 (1) ◽  
pp. 47-55
Author(s):  
Ambreen Fatima ◽  
Yasir H. Siddique

The novel coronavirus disease (COVID-19) has entered a threatening stage all over the world. Many lives have been lost, and many more are in need of treatment. The mild symptoms may include fever and dry cough, but in severe cases, it could lead to pneumonia and ultimately death in some instances. Though medical scientists all over the globe are working hard to develop a treatment for this disease, yet no definite cure has been found. To date, the treatment strategy is based on adopting strategies to break the transmission of the virus and repurposing of the old drugs to prevent the loss of life. Among the various potent candidates, flavonoids may play a protective role in these times. Studies have already proven various health-promoting properties of flavonoids in earlier viral diseases, like SARS and MERS. Since ancient times, been plants have used to treat a number of human diseases. Different phytoproducts have been previously described to inhibit the replication of numerous viruses. Despite the positive reports for plant-based medications, no successful clinical trials on phytoproducts as anti-COVID agents have been conducted to date. This review highlights the efficacy of flavonoids as a treatment strategy either alone or in combination with other drugs.


Sign in / Sign up

Export Citation Format

Share Document